Chemistry: analytical and immunological testing – For preexisting immune complex or auto-immune disease
Reexamination Certificate
2000-08-23
2004-10-26
Nolan, Patrick J. (Department: 1644)
Chemistry: analytical and immunological testing
For preexisting immune complex or auto-immune disease
C435S004000, C435S007100, C435S029000
Reexamination Certificate
active
06808936
ABSTRACT:
TECHNICAL FIELD
The field of this invention is chronic immune disease, particularly chronic fatigue syndrome and multiple sclerosis.
BACKGROUND OF THE INVENTION
Chronic immune diseases can be highly debilitating. Two such chronic immune diseases are multiple sclerosis and chronic fatigue syndrome.
Multiple sclerosis (MS) is a neurological illness of unknown etiology associated with attacks of focal or multi-focal neurological dysfunction arising from lesions within the central nervous system (CNS). In America and Northern Europe, MS is the most common neurological disease, with prevalence rates estimated between 50-100 per 100,000 population. The onset of disease is most common in early adulthood. Recurrent attacks can occur over many years, with approximately 30 percent of the patients progressing to a severe form of the disease which can be fatal.
MS is pleomorphic in its presentation. The clinical manifestations are determined in part by the location of the foci of demyelination within the CNS. Classical features of the disease include impaired vision, nystagmus, dysarthia, ataxia and intention tremor, and weakness/paralysis of one or more limbs.
The most common form of the disease is episodic. Symptoms develop with subsequent recovery, then another attack occurs. In approximately 50 percent of all patients with MS, attacks become more frequent, usually with a worsening of symptomatology. In 30 percent of all patients, the disease develops into what is referred to as progressive/relapsing, the most severe form of the disease. In this state remissions are rare and patients frequently become wheelchair bound.
The characterization of MS disease activity (including diagnosis, determination of disease state, monitoring of disease progression, prediction of disease attacks, and the like), remains problematic. To aid the clinician, the only laboratory test available is testing the cerebrospinal fluid for oligoclonal bands, present in approximately 90 percent of all patients. Examination of the brain for demyelinating plaques, using magnetic resonance imaging (MRI) is useful but expensive, and is not warranted except in a small group of patients in which all other clinical and laboratory tests are negative. Furthermore, there is no diagnostic laboratory test to determine if a patient is having an attack, to monitor the progress of the attack, to determine if the patient is progressing to a more active form of the disease (i.e., progressive/relapsing), etc. Finally, there is no laboratory test available as a prognostic indicator and/or capable of monitoring the course of therapy. One commentator has summarized the situation as follows: “The need for reliable markers of disease activity in multiple sclerosis (MS) to better guide basic research, diagnosis, treatment, and monitoring therapy is well-recognized.” Laman et al. (1998),
Mult. Scler
. 4:266-269.
Like MS, chronic fatigue syndrome (CFS) is an illness of unknown etiology. CFS is often associated with sudden onset, flu-like symptoms, debilitating fatigue, low-grade fever, myalgia and neurocognitive dysfunction. CFS patients typically display reduced Karnofsky performance scores (KPS). The Karnofsky performance test measures an individual's ability to function and carry on normal activities. Karnofsky scores range form zero for a nonfunctional or dead patient to 100 for a completely normal function.
Diagnosis of CFS remains one of exclusion. An accumulating body of evidence suggests that CFS is associated with disregulation of both humoral and cellular immunity, including mitogen response, reactivation of viruses, abnormal cytokine production, diminished natural killer cell function and changes in intermediary metabolites. It has been suggested that the clinical and immunological abnormalities observed in CFS might include defects in the double-stranded RNA (dsRNA)dependent, interferon-inducible pathways, i.e., the 2′,5′-oligoadenylate (2-5A or 2 5 A) synthetase/RNase L and p68 kinase (PKR) antiviral defense pathways (Suhadolnik et al. (1994),
Clin. Infect. Dis
. 18:S96-S104; Suhadolnik et al. (1994),
In Vivo
8:599-604). The 2 5 A synthetase/RNase L pathway is part of the antiviral defense mechanism in mammalian cells; this pathway also has a role in the regulation of cell growth and differentiation (Lengyel, (1982),
Ann. Review Biochem
. 51:251-282; Sen et al. (1 993),
Adv. Virus Res
. 42:57-102).
When activated by dsRNA, 2 5 A synthetase converts ATP to 2′,5′-linked oligoadenylates with 5′-terminal phosphates. Biologically active 2 5 A binds to and activates a latent endoribonuclease, RNase L, which hydrolyzes single-stranded viral and cellular RNA, primarily after UpNp sequences, thereby inhibiting protein synthesis.
Previous studies on the 2 5 A synthetase/RNase L pathway in CFS revealed a statistically significant dysregulation in which the 2 5 A synthetase is present predominantly in its activated form, bioactive 2 5 A levels are elevated, and RNase L activity is upregulated (Suhadolnik et al., Clin. Infect. Dis., supra; Suhadolnik et al., In Vivo, supra). Expression of the serine-threonine kinase, PKR, is downregulated in CFS (Suhadolnik et al., In Vivo, supra). PKR controls initiation of protein translation through phosphorylation of eIF-2.
Despite these efforts, a clear cut molecular marker for CFS has not been identified. What is needed is a biochemical test, relying on an unambiguous molecular marker for CFS, which may form the basis of a definitive CFS diagnosis.
As the above discussion demonstrates, currently employed methods of diagnosing and/or characterizing MS or CFS disease activity in a subject are inadequate. As such, there is a continued need in the field to develop additional means for diagnosing and/or characterizing MS or CFS disease activity in a subject.
In addition, an effective cure for either MS or CFS has yet to be developed. As such, there is continued interest in the identification of new treatment protocols for chronic immune diseases, and particularly for MS and CFS.
Relevant Literature
U.S. Patents of interest include: U.S. Pat. Nos. 5,766,859; 5,776,690; 5,830,668; 5,853,996; and 5,985,565. Also of interest is WO 91/00097. Other references of interest include: Castelli et al. (1997),
J. Exp. Med
. 186:967-972 and Diaz-Guerra et al. (1997),
Virology
236:354-363.
SUMMARY OF THE INVENTION
Methods and compositions are provided for use in the diagnosis and treatment of a host suffering from a chronic immune disease. In the diagnostic methods of the subject invention, a host derived sample, typically PBMC or a derivative thereof, is assayed for the presence of low molecular weight fragments of RNase L, typically in conjunction with an evaluation of caspase activity. The results of this assay are then employed to diagnose and/or characterize a chronic immune disease in the host. In the treatment methods of the subject invention, an effective amount of agent capable of enhancing RNase L homodimer activity in the host, e.g., in host PBMC, is administered to the host Also provided are methods for identifying agents having RNase L cleavage-inhibitory activity, i.e, agents that inhibit the cleavage of RNase L, or RNase L fragment antagonist activity.
REFERENCES:
patent: 5766859 (1998-06-01), Vojdani et al.
patent: 5776690 (1998-07-01), Vojdani et al.
patent: 5830668 (1998-11-01), Mordechai et al.
patent: 5853996 (1998-12-01), Mordechai et al.
patent: 5985565 (1999-11-01), Suhadolnik
patent: 6080554 (2000-06-01), Campine et al.
patent: 6130206 (2000-10-01), Carter
patent: WO 91/00097 (1991-01-01), None
The Merch Manual of Diagnosis and Therapy, 2000.*
Diaz-Guerra, “Activation of the IFN-Inducible Enzyme RNase L Causes Apoptosis of Animal Cells” Academic Press,Virology236, 354-363 (1997), Article No., VY978719.
Castelli, “A Study of the Interferon Antiviral Mechanism: Apoptosis Activation by the 2-5A System”The Journal of Experimental Medicine,vol. 186, No. 6, Sep. 15, 1997 967-972.
De Meirleir Kenny Leo
Englebienne Patrick
Herst Charles Vincent
Bozicevic Field & Francis LLP
Field Bret E.
Nolan Patrick J.
R.E.D. Laboratories N.V.
LandOfFree
Methods and compositions for use in the diagnosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for use in the diagnosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for use in the diagnosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3292788